Relief Therapeutics Holding AG (RLFTF)

[elllk]

If you too early on stop a well designed study that is aimed at convincing the world that this medication is going to be highly beneficial and should be rapidly manufactured and distributed at a fairly high price then cutting the study short for any reason, especially when the study period is not that long, is bound to bring on innumerable criticisms and attacks on validity, especially in this area of so much serious competition between wealthy and powerful companies who will be happy to overlook any justifications, even valid ones, for cutting it short.